MemoryPlus
Cognition Restoring Treatment for Alzheimer’s Disease
Company Overview
Snapshot
Founded in April 2019 by Shira Knafo, MemoryPlus operates with 1–10 employees. The company has secured funding across one round from one investor, with Israel Biotech Fund participating as a lead investor. MemoryPlus is focused on developing an innovative treatment for Alzheimer’s-related cognitive decline.
Business overview
MemoryPlus is a Health Tech & Life Sciences company focused on pioneering an innovative treatment for Alzheimer’s-related cognitive decline. The company's core technology leverages a novel mechanism of action (MOA) based on groundbreaking research by Prof. Shira Knafo, which identified the PTEN protein's critical role in memory decline by inhibiting neuronal activity. By disrupting the interaction between PTEN and PDZ domain proteins, MemoryPlus aims to restore memory function. It operates within the Pharma & Medical Biotechnology sector, specifically in Drugs Discovery & Development, targeting the Healthcare & Life Sciences and Pharmaceutical markets.
Log in to access full profile ›Company Intelligence Q&A
- What is MemoryPlus's primary focus?
- MemoryPlus is focused on developing an innovative treatment for Alzheimer’s-related cognitive decline, leveraging a novel mechanism of action (MOA) to restore memory function.
- Who founded MemoryPlus?
- MemoryPlus was founded by Shira Knafo in April 2019.
- What is the scientific basis of MemoryPlus's treatment?
- MemoryPlus's research is based on the discovery by Prof. Shira Knafo, which found that the PTEN protein inhibits neuronal activity, contributing to memory decline. The company aims to disrupt the interaction between PTEN and PDZ domain proteins.
- In which sector does MemoryPlus primarily operate?
- MemoryPlus operates in the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology and Drugs Discovery & Development.